Rabies G protein vaccine - CPL Biologicals

Drug Profile

Rabies G protein vaccine - CPL Biologicals

Alternative Names: Rabies G protein nanoparticle vaccine - CPL Biologicals; Recombinant nanoparticle rabies vaccine - CPL Biologicals; VLP-based rabies G protein vaccine - CPL Biologicals

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CPL Biologicals
  • Class Protein-vaccines; Recombinant proteins; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Rabies

Most Recent Events

  • 02 Aug 2016 Cadila Pharmaceuticals plans a phase III trial for Rabies in India (IM) (CTRI/2016/08/007137)
  • 10 Mar 2014 Cadila Pharmaceuticals completes enrolment in a phase I/II trial in Rabies in India (CTRI/2014/04/004538)
  • 22 Jan 2014 Phase-I/II clinical trials in Rabies in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top